SCHEMBL266677

SCHEMBL266677

CCc1ccc(C(=O)Nc2ccc(Br)cc2C(=O)N/N=C\c2ccc(Cl)c(C(F)(F)F)c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
PLEC Q15149 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
MAPT P10636 5/20 0.41
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
HPGD P15428 3/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 2/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
SLC34A2 O95436 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
PKM P14618 3/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266678 1.00 POLB (0.41) POLBTDP1PLECCTDSP1MAPT
SCHEMBL274042 1.00 POLB (0.41) POLBTDP1PLECCTDSP1MAPT
SCHEMBL266953 0.87 SLC34A2 (0.43) POLBTDP1PLECCTDSP1MAPT
SCHEMBL266954 0.87 SLC34A2 (0.43) POLBTDP1PLECCTDSP1MAPT
SCHEMBL274094 0.87 SLC34A2 (0.43) POLBTDP1PLECCTDSP1MAPT
SCHEMBL274240 0.87 SLC34A2 (0.38) POLBTDP1PLECCTDSP1MAPT
SCHEMBL274103 0.87 SLC34A2 (0.42) POLBTDP1PLECCTDSP1MAPT
SCHEMBL266788 0.87 SLC34A2 (0.49) KDM4EALDH1A1SLC34A2
SCHEMBL269029 0.87 SLC34A2 (0.42) POLBTDP1PLECCTDSP1MAPT
SCHEMBL273425 0.87 SLC34A2 (0.49) KDM4EALDH1A1SLC34A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 POLB 3843/4885TDP1 4744/4885PLEC 1101/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 POLB 3761/4885TDP1 4604/4885PLEC 633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.